JAK2 V617F mutation is not associated with thrombosis in behcet syndrome

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 4, 2012, Pages 421-426

  Ar, M Cem ^a   Hatemi, Gülen ^b   Ekizoǧlu, Seda ^b   Bilgen, Hülya ^c   Saçli, Sevgi ^b   Buyru, A Nur ^b   Soysal, Teoman ^b   Ülkü, Birsen ^b   Yazici, Hasan ^b  

^a ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Behcet Syndrome; JAK2; myeloproliferative neoplasia; thrombosis

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 V617F; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEHCET DISEASE; BLOOD DONOR; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; BEHCET SYNDROME; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; THROMBOSIS;

EID: 84863500410     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611427440     Document Type: Article

References (59)

1. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
3. Baxter EJ, Scott LM, Campbell PJ, et al. (Cancer Genome Project). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
4. Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2004;128(3):275-290.
5. Pearson TC. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost. 1997;23(5):433-439. (Pubitemid 27501783)
6. Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC, et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol. 2008;87(4):269-276. (Pubitemid 351445287)
7. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5): 523-530. (Pubitemid 40592168)
8. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007;35(5):702-711. (Pubitemid 46601748)
9. Wong RS, ChengCK, Chan NP, et al. JAK2V617Fmutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia. Br J Haematol. 2008;141(6):902-904. (Pubitemid 351724863)
10. Remacha AF, Estivill C, Sarda MP, et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica. 2007;92(2):285-286. (Pubitemid 46852446)
11. Bayraktar Y, Harmanci O, Büyükasik Y, et al. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci. 2008;53(10):2778-2783.
12. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. Thromb Haemost. 2007;5(4):708-714. (Pubitemid 46563568)
13. Karimi O, Crusius JBA, Coucoutsi C, et al. JAK2 V617F mutation is not involved in thromboembolism in IBD. Inflamm Bowel Dis. 2008;14(11):1606-1607.
14. Fouassier M, Girodon F, Cleyrat C, et al. Absence of JAK2- V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis. Thromb Haemost. 2009;102(1):180-182.
15. Yazici H, Yurdakul S, Hamuryudan V. Behçet's syndrome. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. 2nd ed. Oxford: Oxford University Press; 1998:1394-1402.
16. Duzgun N, Ates A, Aydintug OT, Demir O, Olmez U. Characteristics of vascular involvement in Behçet's disease. Scand J Rheumatol. 2006;35(1):65-68. (Pubitemid 43247259)
17. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82(1):60-76. (Pubitemid 36139801)
18. Sarica-Kucukoglu R, Akdag-Kose A, Kayabal IM, et al. Vascular involvement in Behcet's disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006;45(8):919-921. (Pubitemid 44145024)
19. Gül A. Behçet's diease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19(5 suppl 24):S6-S12.
20. Özoran K, Düzgün N, Gürler A, Tutkak H, Tokgöz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antitrombin III levels in Behçet's disease. Scand J Rheumatol. 1995;24(6):376-382. (Pubitemid 26046453)
21. Alpagut U, Ugurlucan M, Dayioglu E. Major arterial involvement and review of Behcet's disease. Ann Vasc Surg. 2007;21(2): 232-239. (Pubitemid 46367534)
22. Haznedaroǧlu I, Özcebe OI, Özdemir O, Celik I, Dündar SV, Kirazli S. Impaired haemostatic kinetics and endothelial function in Behçet's disease. J Inter Med. 1996;240(4):181-187. (Pubitemid 26356039)
23. Koç Y,Güllü I, Akpek G, et al. Vascular involvement in Behcet's disease. J Rheumatol. 1992;19(3):402-410.
24. Ricart JM, Ramón LA, Vayá A, et al. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. Br J Haematol. 2008;141(5):716-719. (Pubitemid 351667617)
25. Dönmez A, Aksu K, Aydin H, et al. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet disease and their association with thrombosis. Thromb Res. 2010;126(3):207-210.
26. Espinosa G, Font J, Tàssies D, et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112(1):37-43. (Pubitemid 34113853)
27. Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Behçet's disease and risk of venous thrombosis. Br J Haematol. 2004;126(4):550-556. (Pubitemid 39093098)
28. Lenk N, Özet G, Alli N, Coban O, Erbaşi S. Protein C and protein S activities in Behçet's disease as risk factors of thrombosis. Int J Dermatol. 1998;37(2):124-125. (Pubitemid 28194711)
29. La Regina M, Orlandini F, Prisco D, Dentali F. Homocysteine in vascular Behcet's disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 2010;30(10):2067-2074.
30. Ricart JM, Vayá A, Todolí J, et al. Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost. 2006; 95(4):618-624.
31. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis. 2004;63(11):1445-1449. (Pubitemid 39433949)
32. Gül A, Özbek A, Öztürk C, Inanç M, Koniçe M, Ozçelik T. Coagulation factor V gene mutations increases the riks of venous thrombosis in Behcet's disease. Br J Rheumatol. 1996;35(11): 1178-1180.
33. Verity DH, Vaughan RW, Madanat W, et al. Factor V Leiden is associated with ocular involvement in Behçet's disease. Am J Ophthalmol. 1999;128(3):352-356. (Pubitemid 29413233)
34. Toydemir PB, Elhan AH, Tükün A, et al. Effect of factor V gene G1691A, methylenetetrahydrofolate recuctase gene C677 T and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behçet's disease. J Rheumatol. 2000;27(12):2849-2854.
35. Thiele J, Pierre R, Imbert M, et al. Polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia. In: Jaffe ES, Harris NL, Stein H, Varidman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon, France: IARC Press; 2001: 32-44.
36. Thiele J, Kvasnicka HM, Tefferi A, et al. Polycythemia vera, primary myelofibrosis, essential thrombocythemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Varidman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008: 40-50.
37. Wechsler B, Davatchi F, Mizushima Y, et al. (International Study Group for Behçet's Disease). Criteria for diagnosis of Behçet's disease. Lancet. 1990;335(8697):1078-1080.
38. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
39. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet disease. Curr Opin Rheumatol. 2005;17(1):1-8. (Pubitemid 40075641)
40. Barbui T, Firazzi G, Negri M, et al. (Gruppo Italiano Studio Policitemia). Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123(9): 656-664.
41. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10): 4922-4929.
42. Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113(22):5617-5623.
43. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791-1798.
44. Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behçet's disease. Arthritis Care Res. 2009;61(4): 518-526.
45. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999;78(12):539-543. (Pubitemid 30009355)
46. Bang S, Lee JS, A JY, et al. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. Thromb Haemost. 2009;101(3):547-551.
47. Zerjavic K, Zagradisnik B, Stangler Herodez S, Lokar L, Glaser Krasevac M, Kokalj Vokac N. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis. Acta Haematol. 2010; 124(1):49-56.
48. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica. 2008;93(9):1412-1414.
49. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2008;33(1):67-73.
50. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F JAK2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124(4):409-417.
51. Pardanani A, Lasho TL, Schwager S, et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia. 2007;21(8):1828-1829. (Pubitemid 47086776)
52. Rossi D, Cresta S, Destro T, et al. JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. Br J Haematol. 2007;138(6):813-814. (Pubitemid 47313208)
53. Ugo V, Le Gal G, Lecucq L, Mottier D, Oger E, EDITH Collaborative Study Group. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. Thromb Haemost. 2007; 6(1):203-205.
54. Vannucchi AM. JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep. 2010;5(1):22-28.
55. Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M. JAK2 (V617F) mutation in healthy individuals. Br J Haematol. 2007; 136(4):678-679. (Pubitemid 46148209)
56. Xu X, Zhang Q, Luo J, et al. JAK2 (V617F): prevalence in a large Chinese hospital population. Blood. 2007;109(1):339-342. (Pubitemid 46053075)
57. Akar N. Factor V1691GA mutation in a healthy Turkish population. Turk J Hematol. 2009;26(1):9-11.
58. Lensen R, Rosendaal F, Vandenbroucke J, Bertina R. Factor V Leiden: the venous thrombotic risk in thrombophilic families. Br J Haematol. 2000;110(4):939-945.
59. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. Thromb Haemost. 2007;5(4):859-861. (Pubitemid 46563588)